Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy

Investing.com12-17

Investing.com -- Jefferies upgraded Bristol-Myers Squibb Company (NYSE:BMY) to "buy" from "hold" and raised its price target by $7 to $70, amid an improved confidence in the company’s product pipeline...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492261022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 01:48","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492261022","market":"us","top_or_hot":-1,"title":"Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy","media":"Investing.com","content":"<div>\n<p>Investing.com -- Jefferies upgraded Bristol-Myers Squibb Company (NYSE:BMY) to \"buy\" from \"hold\" and raised its price target by $7 to $70, amid an improved confidence in the company’s product pipeline...</p>\n\n<a href=\"https://finance.yahoo.com/news/jefferies-upgrades-bristol-myers-squibb-174803215.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 01:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/jefferies-upgrades-bristol-myers-squibb-174803215.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- Jefferies upgraded Bristol-Myers Squibb Company (NYSE:BMY) to \"buy\" from \"hold\" and raised its price target by $7 to $70, amid an improved confidence in the company’s product pipeline...</p>\n\n<a href=\"https://finance.yahoo.com/news/jefferies-upgrades-bristol-myers-squibb-174803215.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYE","symbol_name":"Myers Industries Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/jefferies-upgrades-bristol-myers-squibb-174803215.html","article_id":"2492261022","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492261022","pubTimestamp":1734371283,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com --Jefferies upgraded Bristol-Myers Squibb Company  to \"buy\" from \"hold\" and raised its price target by $7 to $70, amid an improved confidence in the company’s product pipeline, disciplined spending, and greater clarity on regulatory risks.The brokerage highlighted the potential of BMY’s schizophrenia drug, Cobenfy, forecasting it to become a $10 billion-plus product.Jefferies noted positive momentum from recent launches, including Cobenfy’s label hitting best-case scenarios, and projected stronger-than-expected sales for 2024 and 2025.It also expressed optimism about Cobenfy’s Alzheimer’s psychosis trials, assigning a 70% probability of success for a key Phase 3 study, and pointed to the drug’s potential efficacy in bipolar disorder, with trials expected to begin in mid-2025.Bristol Myers remains exposed to loss of exclusivity risks for over 70% of its revenues, but Jefferies said the company’s improved visibility on financial performance and promising pipeline justified ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"MYE":"Myers Industries Inc","BMY":"施贵宝"},"translate_title":"杰富瑞(Jefferies)将百时美施贵宝(Bristol Myers Squibb)的药物Cobenfy评级上调至“买入”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1,"MYE":1},"content_text":"Investing.com -- Jefferies upgraded Bristol-Myers Squibb Company (NYSE:BMY) to \"buy\" from \"hold\" and raised its price target by $7 to $70, amid an improved confidence in the company’s product pipeline, disciplined spending, and greater clarity on regulatory risks.\nThe brokerage highlighted the potential of BMY’s schizophrenia drug, Cobenfy, forecasting it to become a $10 billion-plus product.\nJefferies noted positive momentum from recent launches, including Cobenfy’s label hitting best-case scenarios, and projected stronger-than-expected sales for 2024 and 2025.\nIt also expressed optimism about Cobenfy’s Alzheimer’s psychosis trials, assigning a 70% probability of success for a key Phase 3 study, and pointed to the drug’s potential efficacy in bipolar disorder, with trials expected to begin in mid-2025.\nBristol Myers remains exposed to loss of exclusivity risks for over 70% of its revenues, but Jefferies said the company’s improved visibility on financial performance and promising pipeline justified the upgrade.\nRelated Articles\nJefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy\nStocks rise, Nasdaq at record high as Fed decision, data awaited\nShein weighs sale of less than 10% of company in London IPO, sources say","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492261022"}